

MINI REVIEW



Leukocyte trafficking: Mechanisms, molecules, and medical implications

Emre Wahiba

Department of Biochemistry, University of Nigeria, Enugu State, Nigeria

ABSTRACT

Leukocyte trafficking is a vital process that governs the movement of white blood cells throughout the body to maintain immune surveillance, respond to infection, and resolve inflammation. This complex, multistep process involves leukocyte rolling, activation, firm adhesion, transmigration across endothelial barriers, and interstitial migration, orchestrated by an intricate network of adhesion molecules, chemokines, and receptors. Dysregulation of leukocyte trafficking is implicated in numerous pathological conditions, including autoimmune diseases, chronic inflammation, cancer, and transplant rejection. Recent advances in understanding the molecular and cellular mechanisms of leukocyte migration have led to the development of targeted therapies that modulate immune cell movement, offering promising treatment strategies. This review explores the core mechanisms and key molecules involved in leukocyte trafficking, highlights disease-specific implications, and examines current and emerging therapeutic approaches that leverage this critical biological process.

KEYWORDS

Chemokines; Leukocyte trafficking; Chronic inflammation; Dendritic cells; Lymphocytes

ARTICLE HISTORY

Received 24 February 2025;
Revised 13 March 2025;
Accepted 21 March 2025

Introduction

Leukocyte trafficking the process by which white blood cells (leukocytes) move throughout the body is central to immune surveillance, inflammation, and tissue homeostasis. These dynamic movements enable the immune system to detect, respond to, and resolve infections or injuries. Dysregulation of this process contributes to various pathological conditions, including autoimmune diseases, chronic inflammation, cancer, and transplant rejection. This article explores the key mechanisms and molecules involved in leukocyte trafficking and discusses the implications for medical science and therapy.

Overview of Leukocyte Trafficking

Leukocyte trafficking involves a complex interplay of cellular and molecular events that regulate the exit of leukocytes from the bloodstream and their migration into tissues. This process is crucial during immune surveillance under homeostatic conditions and becomes more pronounced during infection or injury [1].

The trafficking process can be broadly divided into: Leukocyte mobilization from primary (bone marrow, thymus) and secondary lymphoid organs. Circulation through blood and lymphatic systems. Endothelial adhesion and transmigration into tissues. Interstitial migration to the site of infection or injury [2].

Table 1. Key molecules in Leukocyte trafficking.

Molecule Type	Examples	Function
Selectins	L-selectin, E-selectin, P-selectin	Mediate initial leukocyte rolling on endothelium
Integrins	LFA-1 (CD11a/CD18), VLA-4	Facilitate firm adhesion to endothelium
Immunoglobulin Superfamily	ICAM-1, VCAM-1	Ligands for integrins on leukocytes
Chemokines	CXCL8 (IL-8), CCL2, CXCL12	Attract and activate leukocytes through GPCRs
Chemokine Receptors	CXCR1, CCR2, CCR7	Bind chemokines and activate integrins
Other Molecules	PECAM-1, JAM-A, CD99	Involved in leukocyte transmigration

Key Steps in Leukocyte Trafficking

Rolling

Leukocytes loosely attach to the endothelial wall and roll along the blood vessel surface, primarily mediated by selectins. This step is critical for slowing down leukocytes to allow stronger adhesive interactions [3].

Activation

Chemokines presented on the endothelial surface activate leukocyte integrins through G protein-coupled receptors (GPCRs), enhancing their affinity for endothelial ligands [4].

Firm adhesion

Activated integrins bind tightly to immunoglobulin superfamily molecules such as ICAM-1 and VCAM-1, anchoring leukocytes to the endothelium [5].

Transmigration (Diapedesis)

Leukocytes transmigrate through the endothelial junctions (paracellular route) or directly through endothelial cells (transcellular route), entering the underlying tissue [6].

Key Molecules in Leukocyte Trafficking

The orchestration of leukocyte trafficking relies on a diverse array of adhesion molecules, chemokines, and receptors. The table 1 below summarizes major molecules involved:

*Correspondence: Dr. Emre Wahiba, Department of Biochemistry, University of Nigeria, Enugu State, Nigeria, email: Wahiba.emre@unn.edu.ng

© 2025 The Author(s). Published by Reseapro Journals. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Types of Leukocytes and Their Trafficking Patterns

Different leukocyte subsets follow distinct trafficking patterns and respond to unique chemokine cues:

Neutrophils

Rapid responders to infection. Express CXCR1/2 and respond to IL-8. Use L-selectin for rolling and Mac-1 (CD11b/CD18) for firm adhesion [7-9].

Monocytes

Classical monocytes (CD14⁺⁺CD16⁻) are recruited to inflamed tissues. Non-classical monocytes (CD14⁺CD16⁺⁺) patrol the endothelium. Use CCR2 to respond to CCL2.

T lymphocytes

Naïve T cells home to lymph nodes via high endothelial venules (HEVs) using L-selectin and CCR7. Effector and memory T cells traffic to peripheral tissues depending on inflammation and antigen presence [9].

B lymphocytes

Home to lymphoid organs via CXCR5 (ligand: CXCL13). Activated B cells migrate to bone marrow or sites of inflammation.

Dendritic cells

Immature DCs reside in peripheral tissues and migrate to lymph nodes upon activation via CCR7 [8].

Regulation of Leukocyte Trafficking

Leukocyte trafficking is tightly regulated to ensure immune balance: Endothelial activation: Cytokines like TNF- α and IL-1 β upregulate adhesion molecules. Chemokine gradients: Local chemokine production creates directional signals [10]. Circadian rhythms: Leukocyte movement shows time-of-day variability. Tissue-specific addressins: Help leukocytes home to specific organs (e.g., MAdCAM-1 in the gut) [11].

Clinical and Medical Implications

Understanding leukocyte trafficking has significant translational value in medicine:

Inflammation and autoimmune diseases

Chronic activation of trafficking pathways underlies diseases like rheumatoid arthritis (RA) Excessive leukocyte infiltration of joints. Multiple sclerosis (MS) T cells breach the blood-brain barrier. Inflammatory bowel disease (IBD) Aberrant lymphocyte homing to the gut [12].

Therapies include Natalizumab (anti- $\alpha 4$ integrin) for MS and Crohn's disease. Vedolizumab (gut-specific $\alpha 4\beta 7$ integrin blocker) for IBD [13].

Cancer

Tumors manipulate leukocyte trafficking by recruiting immunosuppressive cells (Tregs, MDSCs). Downregulating chemokines that attract effector T cells. Immunotherapies aim to restore proper trafficking, e.g., Enhancing tumor infiltration by T cells via CXCL9/10 modulation. Blocking tumor-induced recruitment of suppressor cells [14].

Transplantation

In organ transplants, leukocyte trafficking contributes to graft rejection. Strategies to prolong graft survival include: Blocking donor-specific leukocyte entry. Modifying chemokine expression in graft tissues [15].

Infectious diseases

Pathogens exploit trafficking mechanisms: HIV uses CCR5/CXCR4 to infect T cells. Leishmania alters monocyte recruitment to survive in macrophages. Targeting leukocyte movement can enhance pathogen clearance or reduce tissue damage [16].

Therapeutic Targeting of Trafficking Pathways

These interventions offer precision immune modulation but carry risks like infection or malignancy due to impaired surveillance (Table 2).

Table 2. Advances in drug development have yielded biologics and small molecules targeting trafficking.

Drug	Target	Indication
Natalizumab	$\alpha 4$ integrin	Multiple sclerosis, Crohn's disease
Vedolizumab	$\alpha 4\beta 7$ integrin	Ulcerative colitis, Crohn's disease
FTY720 (Fingolimod)	S1P receptor	Multiple sclerosis
Maraviroc	CCR5	HIV infection

Emerging Research and Future Directions

Single-cell sequencing and intravital microscopy are revealing novel insights into cell dynamics. Organoid models and microfluidics enable in vitro simulation of trafficking. AI-based modeling predicts cell migration behavior and drug responses [17-19]. Personalized medicine may allow tailoring therapies based on individual chemokine profiles. Future breakthroughs may involve engineered leukocytes with synthetic trafficking circuits or nanomedicine-based targeted delivery [20].

Conclusions

Leukocyte trafficking is a fundamental component of immune function, governed by a finely tuned network of adhesion molecules, chemokines, and signaling pathways. Understanding its mechanisms provides critical insights into both physiological immune responses and the pathogenesis of diverse diseases. Therapeutic modulation of leukocyte movement represents a powerful approach for treating inflammatory disorders, cancer, and transplant rejection. Continued research into the molecular intricacies of this process holds promise for the development of highly targeted and effective treatments.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

- Wong CH, Heit B, Kubes P. Molecular regulators of leukocyte chemotaxis during inflammation. *Cardiovasc Res.* 2010;86(2): 183-191. <https://doi.org/10.1093/cvr/cvq040>
- Kameritsch P, Renkawitz J. Principles of leukocyte migration strategies. *Trends Cell Biol.* 2020;30(10):818-832. <https://doi.org/10.1016/j.tcb.2020.06.007>

3. Langer HF, Chavakis T. Leukocyte–endothelial interactions in inflammation. *J Cell Mol Med.* 2009;13(7):1211-1220. [https://doi.org/10.1016/S0016-5085\(98\)70328-2](https://doi.org/10.1016/S0016-5085(98)70328-2)
4. Jones DA, Smith CW, McIntire LV. Leucocyte adhesion under flow conditions: principles important in tissue engineering. *Biomater.* 1996;17(3):337-347. [https://doi.org/10.1016/0142-9612\(96\)85572-4](https://doi.org/10.1016/0142-9612(96)85572-4)
5. Wittchen ES. Endothelial signaling in paracellular and transcellular leukocyte transmigration. *Front Biosci: a journal and virtual library.* 2009;14:2522. <https://doi.org/10.2741/3395>
6. Filippi MD. Mechanism of diapedesis: importance of the transcellular route. *Adv Imm.* 2016;129:25-53. <https://doi.org/10.1016/bs.ai.2015.09.001>
7. Wang J. Neutrophils in tissue injury and repair. *Cell Tissue Res.* 2018;371:531-539. <https://doi.org/10.1007/s00441-017-2785-7>
8. Yoshimura T. Chemokine receptors and neutrophil trafficking. *The chemokine receptors.* 2007:71-86. https://doi.org/10.1007/978-1-59745-020-1_5
9. Capucetti A, Albano F, Bonecchi R. Multiple roles for chemokines in neutrophil biology. *Front Immunol.* 2020;11:1259. <https://doi.org/10.3389/fimmu.2020.01259>
10. Habtezion A, Nguyen LP, Hadeiba H, Butcher EC. Leukocyte trafficking to the small intestine and colon. *Gastroenterology.* 2016;150(2):340-354. <https://doi.org/10.1053/j.gastro.2015.10.046>
11. Arseneau KO, Cominelli F. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. *Clin Pharmacol Ther.* 2015 ;97(1):22-28. <https://doi.org/10.1002/cpt.6>
12. Susek KH, Karvouni M, Alici E, Lundqvist A. The role of CXC chemokine receptors 1–4 on immune cells in the tumor microenvironment. *Front Immunol.* 2018;9:2159. <https://doi.org/10.3389/fimmu.2018.02159>
13. Lian G, Mak TS, Yu X, Lan HY. Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors. *Int J Mol Sci.* 2021;23(1):164. <https://doi.org/10.3390/ijms23010164>
14. Zhao Y, Ting KK, Coleman P, Qi Y, Chen J, Vadas M, Gamble J. The tumour vasculature as a target to modulate leucocyte trafficking. *Cancers.* 2021;13(7):1724. <https://doi.org/10.3390/cancers13071724>
15. Schenk AD, Rosenblum JM, Fairchild RL. Chemokine-directed strategies to attenuate allograft rejection. *Clin Lab Med.* 2008 ;28(3):441-454. <https://doi.org/10.1016/j.cl.2008.07.004>
16. Crescioli C. Chemokines and transplant outcome. *Clin Biochem.* 2016;49(4-5):355-362. <https://doi.org/10.1016/j.clinbiochem.2015.07.026>
17. Lee J, Breuer CB, Lee E. Bioengineered in vitro models of leukocyte–vascular interactions. *Biochem Soc Trans.* 2021;49(2):693-704. <https://doi.org/10.1042/BST20200620>
18. Luster AD, Alon R, Von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. *Nat Immunol.* 2005;6(12):1182-1190. <https://doi.org/10.1038/ni1275>
19. Shelton SE, Nguyen HT, Barbie DA, Kamm RD. Engineering approaches for studying immune-tumor cell interactions and immunotherapy. *Iscience.* 2021;24(1). <https://doi.org/10.1016/j.isci.2020.101985>
20. Mackay CR. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. *Nat Immunol.* 2008;9(9):988-998. <https://doi.org/10.1038/ni.f.210>